Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial

Basit Öğe Kaydı
dc.authoridChan, Stephen Lam/0000-0001-8998-5480
dc.authorwosidChan, Stephen Lam/F-9149-2011
dc.contributor.authorTrojan, J.
dc.contributor.authorAbou-Alfa, G. K.
dc.contributor.authorMeyer, T.
dc.contributor.authorCheng, A. -L.
dc.contributor.authorCicin, I.
dc.contributor.authorBolondi, L.
dc.contributor.authorKluempen, H. J.
dc.date.accessioned2024-06-12T11:24:06Z
dc.date.available2024-06-12T11:24:06Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpage243en_US
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.startpage243en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26791
dc.identifier.volume42en_US
dc.identifier.wosWOS:000568159600586en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology Research And Treatmenten_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleAssociation of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trialen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu